Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

This study has been terminated.
(All data collection has completed.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Antoinette J. Wozniak, Barbara Ann Karmanos Cancer Institute Identifier:
First received: February 20, 2007
Last updated: July 15, 2016
Last verified: July 2016

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving pemetrexed disodium and gemcitabine together with bevacizumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and gemcitabine together with bevacizumab works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Biological: bevacizumab
Drug: gemcitabine hydrochloride
Drug: pemetrexed disodium
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients With Stages IIIB/IV Non- Squamous, Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by Antoinette J. Wozniak, Barbara Ann Karmanos Cancer Institute:

Primary Outcome Measures:
  • Progression-free Survival (PFS) [ Time Frame: Up to 12 months ]
    RECIST criteria for tumor progression of at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Secondary Outcome Measures:
  • Response Rate [ Time Frame: Every 8 weeks, for up to 54 months ]
  • Toxicity [ Time Frame: Every two weeks, for up to 54 months ]
  • Time to Treatment Failure [ Time Frame: Every 8 weeks, for up to 54 months ]
  • Overall Survival [ Time Frame: Every 8 weeks, for up to 54 months ]

Enrollment: 39
Study Start Date: May 2006
Study Completion Date: June 2016
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab, gemcitabine hydrochloride

Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days

Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days

Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days.

Biological: bevacizumab
Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
Other Name: Avastin ®
Drug: gemcitabine hydrochloride
Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
Other Name: Gemzar ®
Drug: pemetrexed disodium
Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
Other Name: Alimta®

Detailed Description:



  • Determine the efficacy of pemetrexed disodium, gemcitabine hydrochloride, and bevacizumab in chemotherapy-naïve patients with stage IIIB or IV nonsquamous cell non-small cell lung cancer.


  • Determine the response rate in patients treated with this regimen.
  • Determine the time to treatment failure in patients treated with this regimen.
  • Determine the overall survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: Patients receive pemetrexed disodium IV over 10 minutes, gemcitabine hydrochloride IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive bevacizumab alone in the absence of disease progression or unacceptable toxicity.

After the completion of study treatment, patients are followed periodically for 6 months.

PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologic or cytologic proof of non-squamous non-small cell lung cancer (NSCLC) (adenocarcinoma, bronchioloalveolar, large cell carcinoma).
  • Must have Stage IV or IIIB NSCLC. Patients with Stage IIIB must have a pleural effusion or not be candidates for treatment for locally advanced disease with chemoradiotherapy.
  • Cannot have a tumor with cavitation..
  • Have uni-dimensional measurable or evaluable disease. If disease is within a previous radiation port there must be documented progression.
  • 18 years of age and have a life expectancy of greater than 12 weeks.
  • Must not have had prior chemotherapy for advanced disease.
  • Must have an ECOG performance status of 0-1.
  • With treated brain metastases are eligble. for details.
  • Adequate organ function:

Absolute neutrophil count of > 1.5 x 109/L Platelet count > 100,000/109/L Hemoglobin > 8g/dl Calculated creatinine clearance > 45mL/min using the standard Cockroft and Gault formula Hepatic: bilirubin < 1.5 times the upper limit of normal,alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) < 3 times upper limit of normal. Alkaline phosphatase, AST, ALT < 5 times upper limit of normal is acceptable if liver has tumor involvement. Urine protein:creatinine ratio ≤1.0 at screening

  • Patients of reproductive potential must use an approved contraceptive method during and for 3 months after study.
  • Must sign an informed consent that details the investigational nature of the study according to the institutional and federal guidelines.
  • Registered with the clinical trials office of the institution.

Exclusion Criteria

  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
  • Prior chemotherapy except for erlotinib for advanced disease.
  • Uncontrolled hypertension (Blood pressure of >150/100 mmHg )
  • Unstable angina
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
  • History of myocardial infarction within 6 months prior to day 1
  • History of hemorrhagic or thrombotic stroke or other CNS bleed within 6 months prior to day 1
  • Clinically significant peripheral vascular disease of 61
  • Evidence of bleeding diathesis or coagulopathy. Patients must not require full dose anticoagulants for any reason.
  • Known CNS disease, except for treated brain metastasis Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
  • Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
  • Urine protein:creatinine ratio > or = 1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to Day 0
  • Serious, non-healing wound, ulcer, or bone fracture
  • Evidence of cavitation in the tumor.
  • Intrathoracic lung carcinoma of squamous cell histology Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is unacceptable.
  • Extrathoracic-only squamous cell NSCLC are eligible. Patients with only peripheral lung lesions (of any NSCLC histology) will also be eligible.
  • History of hemoptysis (bright red blood of 1/2 teaspoon or more within 28 days of registration or clinical history of > Grade 2
  • Clinically significant effusions that cannot be drained
  • Inability to comply with study and/or follow-up procedures
  • Previous or concurrent malignancies with the exception of adequately treated squamous cell or basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any other malignancy treated and in clinical remission for more than 3 years.
  • Prior radiation therapy to the target lesion, unless the lesion is clearly progressing and the interval between the most recent radiation therapy and enrollment is at least 4 weeks.
  • Pregnancy or lactating females. All pre-menopausal women should have a negative urine pregnancy test prior to enrollment. All patients of reproductive potential should agree to use an effective contraceptive method.
  • Serious concomitant systemic disorders (including oncologic emergencies) incompatible with the study (at the discretion of the investigator).
  • Inability to interrupt non-steroidal anti-inflammatory agents 2 days before, the day of, and 2 days after the dose of pemetrexed.
  • Disease which cannot be radiologically imaged.
  • Inability to take dexamethasone, folic acid or vitamin B12 administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00438204

United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109-0942
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Antoinette J. Wozniak, MD Barbara Ann Karmanos Cancer Institute
  More Information

Responsible Party: Antoinette J. Wozniak, Principal Investigator, Barbara Ann Karmanos Cancer Institute Identifier: NCT00438204     History of Changes
Other Study ID Numbers: CDR0000531832
P30CA022453 ( US NIH Grant/Contract Award Number )
WSU-2005-008 ( Other Identifier: Barbara Ann Karmanos Cancer Institute )
WSU-036806MP4F ( Other Identifier: Wayne State University - Human Investigation Committee )
Study First Received: February 20, 2007
Results First Received: June 4, 2014
Last Updated: July 15, 2016

Keywords provided by Antoinette J. Wozniak, Barbara Ann Karmanos Cancer Institute:
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
adenocarcinoma of the lung
bronchoalveolar cell lung cancer
large cell lung cancer
recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors processed this record on May 25, 2017